Abstract
Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable “states” that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.
Keywords: Aneuploidy, Chromosomal instability, Cancer, Anticancer drugs, NCI-60, Karyotic abnormalities, CIN, Chromosomal instability phenotype, Heterogeneity, Cancer progression, Chemotherpeutic agents, Anticancer therapy, Drosophila, Trisomies, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neoplasia, Tumorigenesis, Microsatellite instability, CENP-E heterozygous, Chromatid cohesion, Centrosomes, Kinetochore, Chromosome missegregating, JAK-STAT signaling pathways, ECM-receptor interaction pathways, Griseofulvin, Cancer spectrum, GI50 data vectors, Anthracyclines, Antifolates, Alkylators, Topoisomerase agents, Gemcitabine, 5-fluorouracil, Mercapto-3H quinazolines
Current Drug Targets
Title: Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Volume: 11 Issue: 10
Author(s): Anna V. Roschke and Ilan R. Kirsch
Affiliation:
Keywords: Aneuploidy, Chromosomal instability, Cancer, Anticancer drugs, NCI-60, Karyotic abnormalities, CIN, Chromosomal instability phenotype, Heterogeneity, Cancer progression, Chemotherpeutic agents, Anticancer therapy, Drosophila, Trisomies, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neoplasia, Tumorigenesis, Microsatellite instability, CENP-E heterozygous, Chromatid cohesion, Centrosomes, Kinetochore, Chromosome missegregating, JAK-STAT signaling pathways, ECM-receptor interaction pathways, Griseofulvin, Cancer spectrum, GI50 data vectors, Anthracyclines, Antifolates, Alkylators, Topoisomerase agents, Gemcitabine, 5-fluorouracil, Mercapto-3H quinazolines
Abstract: Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable “states” that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.
Export Options
About this article
Cite this article as:
V. Roschke Anna and R. Kirsch Ilan, Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011341
DOI https://dx.doi.org/10.2174/1389450111007011341 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Down-Regulation of Notch1 Expression is Involved in HL-60 Cell Growth Inhibition Induced by 4-Hydroxynonenal, a Product of Lipid Peroxidation
Medicinal Chemistry Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation
Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Effect-based Hazard Identification of House Dust by In Vitro Assays Detecting Dioxin-like Compounds, Thyroid and Reproductive Toxicants
Current Organic Chemistry Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Glutathione Transferases as Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity
Current Medicinal Chemistry Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Fluid-fluid Levels in Musculoskeletal Tumor Imaging
Current Medical Imaging